This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00522/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00522/identifier/drugbank/
n16http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00522/identifier/chebi/
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00522/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00522/identifier/pharmgkb/

Statements

Subject Item
n2:DB00522
rdf:type
n3:Drug
n3:description
Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. It is given by mouth as a noninvasive test. The amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the U.S. or Canada (It was withdrawn in the US in October 1996).
n3:generalReferences
# Toskes PP: The bentiromide test for pancreatic exocrine insufficiency. Pharmacotherapy. 1984 Mar-Apr;4(2):74-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6371722
n3:group
withdrawn
n3:indication
Used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy.
n3:manufacturer
n5:271B6508-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00522 n16:DB00522
dcterms:title
Bentiromide
adms:identifier
n9:D01346 n10:31263 n11:DB00522 n13:PA164750572 n17:Bentiromide
n3:mechanismOfAction
Bentiromide is a peptide that is broken down in the pancreas by chymotrypsin. By determining the output of unchanged bentiromide in the urine following oral administration, it is possible to determine the sufficiency of pancreatic activity.
n3:synonym
Bentiromide BTPABA Bentiromidum PFT Bentiromido
n3:toxicity
Symptoms of overdose include shortness of breath and troubled breathing.
n3:synthesisReference
DeBenneville, P.L.and Greenberger, N.J.; U.S. Patent 3,745,212; July 10,1973; assigned to Rohm & Haas Co.
n6:hasConcept
n7:M0049427
n3:IUPAC-Name
n4:271B650D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6513-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6512-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B650F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6510-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6511-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B650B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6524-363D-11E5-9242-09173F13E4C5 n4:271B6509-363D-11E5-9242-09173F13E4C5 n4:271B650C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B650A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6519-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B651A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6514-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6515-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6517-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6516-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6518-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
37106-97-1
n3:category
n3:Bioavailability
n4:271B651F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6521-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6522-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6523-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B651E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B651D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6520-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B650E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B651B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B651C-363D-11E5-9242-09173F13E4C5